Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease

  • Cleveland Clinic Journal of Medicine
  • September 1995,
  • 62
  • (5)
  • 317-323;

ABSTRACT

SUMMARY Although sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, is still the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease, newer formulations, which release drug to specific regions of the colon for maximal efficacy, also can be appropriate first-line agents. This article reviews recent clinical studies of therapy with older and newer 5-ASA formulations.

INDEX TERMS
View Abstract
Loading
PDF
Back to top

In this issue

Cleveland Clinic Journal of Medicine

Cleveland Clinic Journal of Medicine

Vol. 62, Issue 5

1 Sep 1995

Table of Contents Table of Contents (PDF) Index by author

Jump to section

Keywords

Inflammatory Bowel Disease, Aminosalicylic Acids